285 related articles for article (PubMed ID: 16781199)
1. Preferential in vivo DNA repair of melphalan-induced damage in human genes is greatly affected by the local chromatin structure.
Souliotis VL; Dimopoulos MA; Episkopou HG; Kyrtopoulos SA; Sfikakis PP
DNA Repair (Amst); 2006 Aug; 5(8):972-85. PubMed ID: 16781199
[TBL] [Abstract][Full Text] [Related]
2. Association between transcriptional activity, local chromatin structure, and the efficiencies of both subpathways of nucleotide excision repair of melphalan adducts.
Episkopou H; Kyrtopoulos SA; Sfikakis PP; Fousteri M; Dimopoulos MA; Mullenders LH; Souliotis VL
Cancer Res; 2009 May; 69(10):4424-33. PubMed ID: 19417135
[TBL] [Abstract][Full Text] [Related]
3. Extent of damage and repair in the p53 tumor-suppressor gene after treatment of myeloma patients with high-dose melphalan and autologous blood stem-cell transplantation is individualized and may predict clinical outcome.
Dimopoulos MA; Souliotis VL; Anagnostopoulos A; Papadimitriou C; Sfikakis PP
J Clin Oncol; 2005 Jul; 23(19):4381-9. PubMed ID: 15883412
[TBL] [Abstract][Full Text] [Related]
4. Gene-specific formation and repair of DNA monoadducts and interstrand cross-links after therapeutic exposure to nitrogen mustards.
Souliotis VL; Dimopoulos MA; Sfikakis PP
Clin Cancer Res; 2003 Oct; 9(12):4465-74. PubMed ID: 14555520
[TBL] [Abstract][Full Text] [Related]
5. The repair of melphalan-induced DNA adducts in the transcribed strand of active genes is subject to a strong polarity effect.
Episkopou H; Kyrtopoulos SA; Sfikakis PP; Dimopoulos MA; Souliotis VL
Mutat Res; 2011 Sep; 714(1-2):78-87. PubMed ID: 21762707
[TBL] [Abstract][Full Text] [Related]
6. Melphalan-induced DNA damage in vitro as a predictor for clinical outcome in multiple myeloma.
Dimopoulos MA; Souliotis VL; Anagnostopoulos A; Bamia C; Pouli A; Baltadakis I; Terpos E; Kyrtopoulos SA; Sfikakis PP
Haematologica; 2007 Nov; 92(11):1505-12. PubMed ID: 18024399
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-6 affects melphalan-induced DNA damage and repair in human multiple myeloma cells.
Efferth T; Fabry U; Osieka R
Anticancer Res; 2002; 22(1A):231-4. PubMed ID: 12017294
[TBL] [Abstract][Full Text] [Related]
8. Ongoing activity of RNA polymerase II confers preferential repair of nitrogen mustard-induced N-alkylpurines in the hamster dihydrofolate reductase gene.
Wassermann K; Damgaard J
Cancer Res; 1994 Jan; 54(1):175-81. PubMed ID: 7505196
[TBL] [Abstract][Full Text] [Related]
9. Chromatin structure, transcriptional activity and DNA repair efficiency affect the outcome of chemotherapy in multiple myeloma.
Gkotzamanidou M; Sfikakis PP; Kyrtopoulos SA; Bamia C; Dimopoulos MA; Souliotis VL
Br J Cancer; 2014 Sep; 111(7):1293-304. PubMed ID: 25051404
[TBL] [Abstract][Full Text] [Related]
10. Preferential DNA damage in the p53 gene by benzo[a]pyrene metabolites in cytochrome P4501A1-expressing xeroderma pigmentosum group A cells.
Quan T; States JC
Mol Carcinog; 1996 May; 16(1):32-43. PubMed ID: 8634092
[TBL] [Abstract][Full Text] [Related]
11. Genotypic and phenotypic comparisons of de novo and acquired melphalan resistance in an isogenic multiple myeloma cell line model.
Hazlehurst LA; Enkemann SA; Beam CA; Argilagos RF; Painter J; Shain KH; Saporta S; Boulware D; Moscinski L; Alsina M; Dalton WS
Cancer Res; 2003 Nov; 63(22):7900-6. PubMed ID: 14633719
[TBL] [Abstract][Full Text] [Related]
12. Preferential DNA repair in active genes.
Bohr VA
Dan Med Bull; 1987 Dec; 34(6):309-20. PubMed ID: 3325235
[TBL] [Abstract][Full Text] [Related]
13. Repair of DNA lesions in chromosomal DNA impact of chromatin structure and Cockayne syndrome proteins.
Fousteri M; van Hoffen A; Vargova H; Mullenders LH
DNA Repair (Amst); 2005 Jul; 4(8):919-25. PubMed ID: 15961352
[TBL] [Abstract][Full Text] [Related]
14. Oral mucositis and outcomes of autologous hematopoietic stem-cell transplantation following high-dose melphalan conditioning for multiple myeloma.
Vera-Llonch M; Oster G; Ford CM; Lu J; Sonis S
J Support Oncol; 2007 May; 5(5):231-5. PubMed ID: 17564153
[TBL] [Abstract][Full Text] [Related]
15. Deregulation of homologous recombination DNA repair in alkylating agent-treated stem cell clones: a possible role in the aetiology of chemotherapy-induced leukaemia.
Worrillow LJ; Allan JM
Oncogene; 2006 Mar; 25(12):1709-20. PubMed ID: 16278672
[TBL] [Abstract][Full Text] [Related]
16. Didox, a ribonucleotide reductase inhibitor, induces apoptosis and inhibits DNA repair in multiple myeloma cells.
Raje N; Kumar S; Hideshima T; Ishitsuka K; Yasui H; Chhetri S; Vallet S; Vonescu E; Shiraishi N; Kiziltepe T; Elford HL; Munshi NC; Anderson KC
Br J Haematol; 2006 Oct; 135(1):52-61. PubMed ID: 16925573
[TBL] [Abstract][Full Text] [Related]
17. Sequence-specific p53 gene damage by chloroacetaldehyde and its repair kinetics in Escherichia coli.
Kowalczyk P; Cieśla JM; Saparbaev M; Laval J; Tudek B
Acta Biochim Pol; 2006; 53(2):337-47. PubMed ID: 16582987
[TBL] [Abstract][Full Text] [Related]
18. An in vivo analysis of MMC-induced DNA damage and its repair.
Lee YJ; Park SJ; Ciccone SL; Kim CR; Lee SH
Carcinogenesis; 2006 Mar; 27(3):446-53. PubMed ID: 16258176
[TBL] [Abstract][Full Text] [Related]
19. Deletion of 5q31 and 7q31 in patients with stable melphalan treated multiple myeloma.
Amiel A; Yukla M; Yogev S; Manor Y; Fejgin MD; Lishner M
Cancer Genet Cytogenet; 2004 Jul; 152(1):84-7. PubMed ID: 15193449
[TBL] [Abstract][Full Text] [Related]
20. Topoisomerase II beta levels are a determinant of melphalan-induced DNA crosslinks and sensitivity to cell death.
Emmons M; Boulware D; Sullivan DM; Hazlehurst LA
Biochem Pharmacol; 2006 Jun; 72(1):11-8. PubMed ID: 16678798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
